What is the ROE (Return on Equity) of Novocure this year?
The ROE of Novocure this year is -0.47 undefined.
Novocure ROE 2025
Novocure ROE
-0.47
Ticker
NVCR
ISIN
JE00BYSS4X48
WKN
A140ML
In 2025, Novocure's return on equity (ROE) was -0.47, a -18.03% increase from the -0.57 ROE in the previous year.
Novocure Aktienanalyse
What does Novocure do?
Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Novocure's Return on Equity (ROE)
Novocure's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Novocure's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Novocure's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Novocure’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Novocure stock
How has the Return on Equity (ROE) of Novocure developed compared to the previous year?
The ROE of Novocure has increased by -18.03% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Novocure?
A high ROE indicates that Novocure generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Novocure?
A low ROE can indicate that Novocure is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Novocure affect the company?
A change in ROE (Return on Equity) of Novocure can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Novocure?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Novocure?
Some factors that can influence Novocure's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Novocure pay?
Over the past 12 months, Novocure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novocure is expected to pay a dividend of 0 USD.
What is the dividend yield of Novocure?
The current dividend yield of Novocure is .
When does Novocure pay dividends?
Novocure pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novocure?
Novocure paid dividends every year for the past 0 years.
What is the dividend of Novocure?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novocure located?
Novocure is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novocure kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novocure from 10/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2025.
When did Novocure pay the last dividend?
The last dividend was paid out on 10/5/2025.
What was the dividend of Novocure in the year 2024?
In the year 2024, Novocure distributed 0 USD as dividends.
In which currency does Novocure pay out the dividend?
The dividends of Novocure are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novocure
Our stock analysis for Novocure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novocure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.